Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_assertion type Assertion NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_head.
- NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_assertion description "[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_provenance.
- NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_assertion evidence source_evidence_literature NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_provenance.
- NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_assertion SIO_000772 23313046 NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_provenance.
- NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_assertion wasDerivedFrom befree-20150227 NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_provenance.
- NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_assertion wasGeneratedBy ECO_0000203 NP518947.RABldmynRDrna5tMjb-M73AJTqD39US-YSEapEzmm4dJ4130_provenance.